What is the price of gosatuzumab in india

Sacituzumab govitecan (Sacituzumab govitecan) is a targeted therapy drug used to treat certain types of cancer. It is a complex of antibodies and drugs that works by targeting receptors on the surface of tumor cells. Gosatuzumab, the first antibody-drug conjugate targeting TROP-2, has been approved in nearly 50 countries, with multiple additional regulatory reviews underway around the world. But as of June 2024, there are no relevant Indian pharmaceutical companies producing gosatuzumab original drugs or generic drugs. Medication should be used according to your doctor's instructions and only under your doctor's supervision. Please do not buy and use medicines by yourself to avoid adverse effects.

The trade name of gosatuzumab isTrodelvy, developed by Gilead Sciences. It was approved by the U.S. Food and Drug Administration (FDA) in 2020 for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received 2 or more prior systemic therapies; patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and 2 or more systemic therapies and have metastasized; and patients with locally advanced or metastatic urothelial cancer who have received a PD-(1)1 inhibitor.

Although the original drug of gosatuzumab has been launched in China, it has not been included in the medical insurance catalog. The price of its 180 mg medicine is as high as about 10,000 yuan. Overseas, including Europe, the United States and Singapore, the price of the drug varies due to exchange rate fluctuations, ranging from RMB 10,000 to more than RMB 30,000. However, it is worth mentioning that the ingredients of gosatuzumab sold at home and abroad are similar.